Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

Cited In for PubMed (Select 1710777)

1.

Prevention of Morbidity in sickle cell disease - qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial.

Howard J, Inusa B, Liossi C, Jacob E, Murphy PB, Hart N, Gavlak J, Sahota S, Chorozoglou M, Nwosu C, Gwam M, Gupta A, Rees DC, Thein SL, Reading IC, Kirkham FJ, Cheng MY.

Trials. 2015 Aug 25;16(1):376. doi: 10.1186/s13063-015-0883-y.

2.

Updated Mechanisms of Sickle Cell Disease-Associated Chronic pain.

Lutz B, Meiler SE, Bekker A, Tao YX.

Transl Perioper Pain Med. 2015 Jul 26;2(2):8-17.

3.

Adolescents with sickle cell anaemia: Experience in a private tertiary hospital serving a tertiary institution.

John-Olabode S, Awodele I, Oni O.

Niger Med J. 2015 May-Jun;56(3):204-7. doi: 10.4103/0300-1652.160397.

4.

Genomic approaches to identifying targets for treating β hemoglobinopathies.

Ngo DA, Steinberg MH.

BMC Med Genomics. 2015 Jul 29;8(1):44. doi: 10.1186/s12920-015-0120-2.

5.

Alpha thalassemia among sickle cell anaemia patients in Kampala, Uganda.

Lubega I, Ndugwa CM, Mworozi EA, Tumwine JK.

Afr Health Sci. 2015 Jun;15(2):682-9. doi: 10.4314/ahs.v15i2.48.

6.

Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease.

Detterich JA, Kato RM, Rabai M, Meiselman HJ, Coates TD, Wood JC.

Blood. 2015 Aug 6;126(6):703-10. doi: 10.1182/blood-2014-12-614370. Epub 2015 Jun 2.

PMID:
26036801
7.

Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.

Chou YC, Chen RL, Lai ZS, Song JS, Chao YS, Shen CK.

Mol Cell Biol. 2015 Jul;35(14):2541-53. doi: 10.1128/MCB.00035-15. Epub 2015 May 18.

PMID:
25986606
8.

The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease.

Rees DC, Thein SL, Osei A, Drasar E, Tewari S, Hannemann A, Gibson JS.

Haematologica. 2015 May;100(5):595-600. doi: 10.3324/haematol.2014.120402. Epub 2015 Mar 6.

9.

Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Calhoun G, Wang L, Almeida LE, Kenyon N, Afsar N, Nouraie M, Finkel JC, Quezado ZM.

Eur J Pharmacol. 2015 May 5;754:125-33. doi: 10.1016/j.ejphar.2015.02.027. Epub 2015 Feb 25.

PMID:
25724786
10.

Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).

Adewoyin AS.

Anemia. 2015;2015:791498. doi: 10.1155/2015/791498. Epub 2015 Jan 18. Review.

11.

Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis.

Du E, Diez-Silva M, Kato GJ, Dao M, Suresh S.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1422-7. doi: 10.1073/pnas.1424111112. Epub 2015 Jan 20.

12.

Advances in sickle cell therapies in the hydroxyurea era.

Field JJ, Nathan DG.

Mol Med. 2014 Dec 16;20 Suppl 1:S37-42. doi: 10.2119/molmed.2014.00187.

13.

Randomized trial of hypnosis as a pain and symptom management strategy in adults with sickle cell disease.

Wallen GR, Middleton KR, Ames N, Brooks AT, Handel D.

Integr Med Insights. 2014 Nov 3;9:25-33. doi: 10.4137/IMI.S18355. eCollection 2014.

14.

Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.

Smith TP, Schlenz AM, Schatz JC, Maitra R, Sweitzer SM.

Blood Cells Mol Dis. 2015 Feb;54(2):155-9. doi: 10.1016/j.bcmd.2014.11.016. Epub 2014 Nov 26.

PMID:
25486928
15.

Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania.

Mtatiro SN, Singh T, Rooks H, Mgaya J, Mariki H, Soka D, Mmbando B, Msaki E, Kolder I, Thein SL, Menzel S, Cox SE, Makani J, Barrett JC.

PLoS One. 2014 Nov 5;9(11):e111464. doi: 10.1371/journal.pone.0111464. eCollection 2014.

16.

Update on the use of hydroxyurea therapy in sickle cell disease.

Wong TE, Brandow AM, Lim W, Lottenberg R.

Blood. 2014 Dec 18;124(26):3850-7; quiz 4004. doi: 10.1182/blood-2014-08-435768. Epub 2014 Oct 6. Review. No abstract available.

PMID:
25287707
17.

Using Quality Improvement Methods to Implement an Electronic Medical Record (EMR) Supported Individualized Home Pain Management Plan for Children with Sickle Cell Disease.

Crosby LE, Simmons K, Kaiser P, Davis B, Boyd P, Eichhorn T, Mahaney T, Joffe N, Morgan D, Schibler K, Anderson V, Quinn CT, Kalinyak KA.

J Clin Outcomes Manag. 2014 May;21(5):210-217.

18.

Tramadol use in pediatric sickle cell disease patients with vaso-occlusive crisis.

Borgerding MP, Absher RK, So TY.

World J Clin Pediatr. 2013 Nov 8;2(4):65-9. doi: 10.5409/wjcp.v2.i4.65. eCollection 2013 Nov 8.

19.

Mast cell activation syndrome as a significant comorbidity in sickle cell disease.

Afrin LB.

Am J Med Sci. 2014 Dec;348(6):460-4. doi: 10.1097/MAJ.0000000000000325.

20.

FOETAL HAEMOGLOBIN (HbF) STATUS IN ADULT SICKLE CELL ANAEMIA PATIENTS IN IBADAN, NIGERIA.

Olaniyi JA, Arinola OG, Odetunde AB.

Ann Ib Postgrad Med. 2010 Jun;8(1):30-3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk